Bayer’s hemophilia therapy ‘Kogenate’ voluntarily returned in Korea
Bayer Korea will voluntarily collect back its hemophilia A therapy, Kogenate FS Inj.
It will be a follow-up action to prevent a quality issue since the company encountered disapproval of its products manufactured in foreign countries on qualification.
The company has not found any problem impor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.